The change in the portion of the difference between total income tax expense (benefit) as reported in the Income Statement for the period and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to the subsidy for Medicare prescription drug benefits previously received tax-free before enactment of recent legislation.

This item represents the effect on the entity's effective tax rate attributable to sales of available-for-sale securities.

The entity's best estimate (as of the end of the first and second quarter) of the effective tax rate expected to be applicable for the full fiscal year, excluding the tax impact of significant unusual or extraordinary items that are separately reported.

Amount represents the entity's proportionate share of certain gains and (losses) recorded by its equity method investees in the period. These gains and (losses) are the result of material events or transactions that are abnormal or significantly different from typical activities or are not reasonably expected to recur in the foreseeable future; but not both, and therefore does not meet both criteria for classification as an extraordinary item. The entity has recorded its proportionate share of these items as a component of equity income (loss) - net.

This item represents a decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings.

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit allocated to Income or Loss from asset impairment as a result of unusual or infrequent items.

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit allocated to other matters not otherwise covered by the existing taxonomy, due to unusual or infrequent items.

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit allocated to productivity, integration, restructuring and transaction costs.

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit allocated to transaction gain or loss due to unusual or infrequent items.

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit allocated to uncertain tax matters due to unusual or infrequent items.

This Item represent the net gains related to a exchange of securities net of costs associated with it and also includes gain or loss arising from the disposal of an equity method investment.

The amount of other than temporary impairment losses on available-for-sale equity securities, other than temporary impairment related to credit losses on debt securities, and other than temporary impairment losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis.

Amount represents the initial remeasurement expense associated with the remeasurement of the net assets of a foreign subsidiary that operates in a hyperinflationary economy.

Amount charged against income statement line items in the period for unusual events that are not reasonably expected to recur in the foreseeable future and other charges.

Amount charged against operating income in the period for material events or transactions that are abnormal or significantly different from typical activities or are not reasonably expect to recur in the foreseeable future and such other transactions.

Amount charged against operating income in the period for material events or transactions that are abnormal or significantly different from typical activities or are not reasonably expect to recur in the foreseeable future; but not both, and therefore does not meet both criteria for classification as an extraordinary item.

A ratio calculated by dividing the reported amount of income tax expense attributable to continuing operations for the period by GAAP-basis pretax income from continuing operations.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 47

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Subparagraph 2
-Article 4

The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate shall be the regular tax rate if there are alternative tax systems.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 47

The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph a, b

The net amount of all increases and decreases in unrecognized tax benefits for the period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 21
-Subparagraph a